Quarterly report pursuant to Section 13 or 15(d)

GENERAL (Details Narrative)

v3.21.2
GENERAL (Details Narrative)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jul. 15, 2021
USD ($)
Jul. 02, 2021
USD ($)
Integer
$ / shares
Apr. 19, 2021
USD ($)
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
Mar. 31, 2021
USD ($)
Jul. 28, 2020
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Feb. 27, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Cash deposits     $ 1,250                
Fair value market deposit shares       $ 1,500              
Debt Instrument, Convertible, Conversion Price | $ / shares       $ 0.05              
Number of shares issued value       $ 1,699              
Accumulated losses       61,448 $ 47,281            
Working capital       4,166              
Shareholders' deficit       8,999 11,011 $ 19,458   $ 4,650 $ 6,263 $ 6,249  
Proceeds from issuance of financial instruments       10,312 10,685            
Recognized revenue       6,763 $ 5,031            
Third Party [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Fair value of convertible debt       $ 4,989              
Subsequent Event [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Second cash payment   $ 1,250                  
Additional amount of cash payment $ 250                    
Convertible notes payable   $ 3,500                  
Maturity date description   October 20, 2021 through April 8, 2025                  
Debt instrument trading days | Integer   20                  
Payments for repurchase amount   $ 1,170                  
Subsequent Event [Member] | Minimum [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Debt Instrument, Convertible, Conversion Price | $ / shares   $ 0.05                  
NIS [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Ordinary shares, par value | $ / shares       $ 0.01 $ 0.01            
Provista Diagnostics Inc [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of stock, percentage     100.00%                
Breakthrough Diagnostics Inc [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Percentage of issued and outstanding common stock                     0.1999
Remaining percentage of issued and outstanding common stock             0.8001        
Share Purchase Agreement [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Number of shares issued as non-refundable | shares       29,296,875              
Share Purchase Agreement [Member] | Provista Diagnostics Inc [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of stock value of shares issued in transaction     $ 7,500                
Share Purchase Agreement [Member] | Provista Diagnostics Inc [Member] | Preferred Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Stock issued during period shares purchase | shares     3,599                
Share Purchase Agreement [Member] | Provista Diagnostics Inc [Member] | Ordinary Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Stock issued during period shares purchase | shares     1,581